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Introduction
Multiple sclerosis is an autoimmune disorder of the cen-
tral nervous system that often manifests with optic neuri-
tis (ON) as well as motor, sensory or cerebellar deficits in 
its earliest stage.1 Current diagnostic criteria for MS 
require proof of dissemination of lesions or attacks in 
time and space.2 In everyday clinical practice, patients 
presenting with a first clinical event that is highly indica-
tive of MS are often instead diagnosed with a clinically 
isolated syndrome (CIS) or ‘possible’ MS.3 A confirmed 
diagnosis of MS is possible once additional attacks or 
lesions present, as is the case for a significant proportion 
of such patients.2
In light of this, pinpointing the aspects of CIS that are 
most predictive for subsequent diagnosis with MS has high 
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priority3 so that patients at risk can be identified. Diagnosing 
MS as early as possible and thus allowing for the widest 
range of therapeutic options, is therefore highly in the 
patients’ interest, in particular as irreversible axonal and 
neuronal injury is a key aspect and correlate of disability in 
MS in early disease stages.3–5
One easily-accessible means of assessing neuroaxonal 
damage in MS is the investigation of the retina. Optical 
coherence tomography (OCT) has shown specific retinal 
alterations in MS patients:6 the retinal nerve fiber layer 
(RNFL) is reduced in MS,7 not only in eyes with a history of 
ON8 but also in eyes without any previous clinical event of 
ON.9,10 Additionally, microcystic macular edema (MME) in 
the inner nuclear layer (INL) has been reported in a subset of 
MS patients.11 Although MME might not be specific to MS, 
but instead ON-dependent,12 the INL has become a key focus 
of clinical investigation of MS pathology after a postmortem 
histopathology study reported neuronal loss in the INL.13,14
Additionally, retinal changes in MS do not merely reflect 
the visual system, but potentially also overall disease 
pathology. RNFL thinning correlates closely with brain 
atrophy,15–17 and with reduction of N-acetyl-aspartate as 
marker of neuroaxonal integrity in the visual cortex.18
These findings suggest that the retina and, in particular, 
intraretinal layers may be an effective means of detecting 
subtle neuronal and axonal damage already present in 
CIS. To investigate this theory, we performed a cross-sec-
tional study analysing intraretinal changes in CIS patients. 
We were especially interested in retinal pathology in eyes 
that had not suffered from previous ON and therefore 
applied a rigorous classification of eyes not only on clini-
cal assessments but also visual evoked potentials (VEP).
Methods
Study participants
Patients were prospectively recruited from outpatient clin-
ics at two university medical centers (Berlin and 
Düsseldorf). Inclusion criteria were clinical and paraclini-
cal (MRI, CSF, EP) diagnosis of CIS suggestive of MS 
after relevant differential diagnoses had been ruled out, and 
an age between 18 and 65 years.2 Patients received MRI to 
exclude the possibility that the disease had developed into 
MS since first diagnosis of CIS. Neurological disability 
was assessed according to the Expanded Disability Status 
Scale (EDSS).19 A history of ON was diagnosed by a treat-
ing physician and was cross-checked using medical records. 
Patients with a refractive error of more than ±5.0 dioptres 
or with any history of eye disease that could impact OCT 
measurements (i.e. glaucoma) were excluded. A second 
exclusion criterion was steroid therapy within 30 days prior 
to examination. A group of healthy controls matched by age 
(+/−3 years) and gender was recruited from patients’ family 
members, medical staff or volunteers. Both centres assessed 
the matched controls to their patients. To exclude potential 
centre effects, we additionally performed centre-specific 
analysis or included centre as covariate. In these analyses, 
centre did not have a significant effect (data not shown). 
Local ethics committees approved the study and all partici-
pants gave written informed consent.
Visual evoked potentials
VEP were either performed during the clinical work-up or as 
part of the study protocol prior to or on the same day as the 
OCT assessment. We used the P100 latency values as a 
parameter to prove optic nerve conduction slowing poten-
tially related to a history of ON. VEP amplitude was not ana-
lysed because the two centres involved in the study performed 
VEP using different devices in a non-standardized manner.
Optical coherence tomography
Experienced operators performed OCT on un-dilated 
eyes using Heidelberg Spectralis SD-OCT (Heidelberg 
Engineering, Germany). All scans were checked for appro-
priate image quality. All participants were examined using 
the peripapillary ring scan, which measures RNFL thickness 
(pRNFL) around the optic nerve head in a circle with an 
angle of 12°, resulting in a diameter of 3.4 mm (example 
shown in Figure 1(a)). Macular volume was assessed by a 
custom scan comprising 61 vertical B-scans (each with 768 
A-Scans, Automatic Real-Time (ART) = 13 frames) with a 
scanning angle of 30° × 25° focusing on the fovea. Using this 
scan, TMV and intra-retinal layers thicknesses were deter-
mined within a cylinder of 6 mm diameter (Figure 1(b)).
Intraretinal layer segmentation
Heidelberg Engineering provided beta software that 
employed a multilayer segmentation algorithm for macular 
volume scans. To analyse the inner retinal layers, a subset of 
B-scans were segmented and manually corrected by an 
experienced assessor in a blinded fashion. The multilayer 
analysis was performed on the central B-scan through the 
fovea and on six B-scans each in nasal and temporal direc-
tion. Manual correction of automatically segmented B-scans 
is a time-consuming step. As a compromise, we manually 
corrected every fourth B-scan, thus analysing an area largely 
covering the 6 mm diameter ETDRS grid with a distance 
between adjacent B-scans of approximately 500 µm. For the 
combined analysis of both eyes, thickness maps of the left 
eye were mirrored vertically to match the topology of the 
right eye. The mean thickness maps within each of the study 
groups were calculated for the four innermost retinal layers: 
macular RNFL (mRNFL), ganglion cell layer (GCL), inner 
plexiform layer (IPL) and INL (Figure 1(c)). Because dif-
ferentiating between GCL and IPL proved to be a hurdle, 
we used the combined thickness of GCL and IPL (GCIPL). 
Please see the supplementary data for individual analyses 
of GCL and IPL. By subtracting the group-specific mean 
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Figure 1. Examples of regions analysed in OCT.
A) Scanning laser ophthalmoscopy image showing the region of the peripapillary ring scan (green); B) Scanning laser ophthalmoscopy image of the 
macular scan with the blue circle indicating the area for total macular volume and intraretinal layer thickness determination; C) 3D reconstruction of 
a macular volume scan, depicting the identified intraretinal layers.
Abbreviations: RNFL = retinal nerve fibre layer; GCL = ganglion cell layer; IPL = inner plexiform layer; INL = inner nuclear layer; OPL = outer plexiform 
layer; ONL = outer nuclear layer; ELM = external limiting membrane; IS/OS = inner segments / outer segments; RPE = retinal pigment epithelium.
thickness maps we produced spatial difference maps 
(Figure 3), in which negative values indicate a thinning of 
the patients’ group compared to matched healthy controls, 
whereas positive values indicated thickening.
Statistical analysis
Generalized estimation equation models (GEE) accounting 
for within-subject inter-eye effects were used to compare 
OCT results between the study cohorts. For the subgroup 
analysis, only controls that were matched to the respective 
CIS patients’ eyes (NON, SON, ON) were used. Correlations 
between VEP and OCT results were performed by linear 
regression. All statistical analyses were performed and all 
figures were created using R version 2.15.0. Statistical sig-
nificance was established at p < 0.05.
Results
Study participants
In total, 45 patients (Berlin 29, Düsseldorf 16) were enrolled 
and compared to matched healthy controls (Berlin 29, 
Düsseldorf 16). All patients were diagnosed with CIS at the 
time of OCT examination and diagnosis and non-progres-
sion towards MS was confirmed by means of MRI. Of the 
patients, 16 had unilateral optic neuritis (seven on the right, 
10 on the left) and 14 patients presented with spinal cord 
symptoms. Six patients experienced relapses with findings 
suggestive of infratentorial brain lesions, in seven patients 
supratentorial signs were found, and one patient exhibited 
both supratentorial and spinal clinical signs. Examination 
of one patient’s eye did not pass the quality criteria due to 
image artefacts and was excluded. Demographic and clini-
cal data are summarized in Table 1.
ON classification according to VEP latency 
and correlation to standard OCT results
As a clinical diagnosis of ON may have been missed by 
patients or physicians, we created another category of 
subclinical (or suspected) ON in eyes without a clinical 
ON history, as assessed by VEP. In addition to the group 
of confirmed ON eyes (CIS-ON), we defined a group of 
suspected ON eyes (CIS-SON), defined as eyes with 
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prolonged P100 latency of over 115 ms but, as stated 
above, without a clinical history of ON. The latter value 
of a 115 ms limit for normal eyes is in accordance with 
literature20 and proved an effective means of distinguish-
ing between eyes diagnosed with ON and unaffected 
eyes (Figure 2(a) and 2(b)). In total, seven eyes were 
classified as CIS-SON. Both eyes of two patients were 
classified as suspected ON and all other CIS-SON eyes 
were contralateral to CIS-ON eyes. Figure 2(a) shows 
the correlation between P100 latencies and pRNFL 
thickness, while Figure 2(b) is a graph of the relation-
ship between the TMV and the VEP results. Linear 
regression showed significant correlation between 
pRNFL and P100 VEP latencies in all CIS eyes (R2 = 
0.243, p < 0.001) and in CIS-NON eyes (R2 = 0.065, p 
= 0.039) but not in CIS-SON and CIS-ON eyes. 
Similarly, TMV correlated significantly to P100 laten-
cies for all CIS eyes (R2 = 0.124, p < 0.001), but not 
for the other subgroups.
pRNFL and TMV comparison
When compared to the corresponding age- and sex-matched 
controls, pRNFL thickness was reduced in CIS-ON (p < 
0.001) and CIS-SON (p = 0.014) but not in CIS-NON eyes 
(p = 0.636) (Figure 2(c)). Analysis of macular scans 
revealed significant TMV reduction in CIS-ON eyes 
(p < 0.001) and, importantly, also in CIS-NON eyes (p = 
0.031) versus controls (Figure 2(d)). TMV reduction in the 
7 CIS-SON eyes was not significant.
Figure 2. VEP and standard OCT results.
Scatterplots showing the relationship of the VEP P100 latencies with A) peripapillary RNFL (pRNFL) and B) total macular volume. The red dashed line 
at 115 ms indicates the threshold between CIS-NON and CIS-SON eyes. The black line is the result of the linear regression including all CIS eyes 
with the standard error given as gray shadow. Comparison of C) peripapillary RNFL thickness and D) total macular volume between the different 
CIS groups and the matching controls. Significant differences are marked with * (p < 0.05), ** (p < 0.01) and *** (p < 0.001).
Abbreviations: HC = healthy control eyes; CIS-NON = patient eyes without history of optic neuritis and VEP P100 ≤115 ms; CIS-SON = eyes with 
VEP P100 latency > 115 ms but no ON diagnosis; CIS-ON = patient eyes with clinical ON diagnosis.  
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Table 1. Demographical and clinical parameters.
CIS HC
Subjects N 45 45
Eyes N total 89 90
N with diagnosed ON 16 NA
N with suspicion ON  7 NA
Age (years) Mean (SD) 31.92 (7.95) 31.67 (7.80)
Min–Max 19.13–56.25 18.64–54.20
Gender N female (%) 31 (68.89) 31 (68.89)
First symptom (months) Mean time between first 
symptom and OCT (SD)
8.60 (12.17) NA
Min–Max 1.37–59.70  
EDSS Median 1 NA
Min–Max 0–4 NA
HC: healthy control; CIS: clinically isolated syndrome; ON: optic neuritis; SD: standard deviation; OCT: optical coherence tomography; Min: minimum; 
Max: maximum, NA: not applicable.
Figure 3. Spatial analysis of changes in CIS eyes versus healthy control eyes.
A) Changes in RNFL thickness between CIS patients and the corresponding group of age- and sex-matched healthy controls. Patients were stratified 
by history of ON: no history of ON (NON), suspected ON (SON) or clinically-diagnosed ON. Reduction in RNFL thickness was evident near the 
optic nerve head (white arrows) in all groups but was more pronounced in SON and ON eyes. B) Thickness changes in the GCIPL were identified 
in the perimacular region and were most evident in CIS-ON eyes. Significant thinning of the GCIPL in CIS-NON eyes compared to the matching 
controls were found in the perimacular area (p = 0.027). C) No group showed significant changes in the INL.
Abbreviations: CIS = clinically isolated syndrome; RNFL = retinal nerve fibre layer; GCIPL = combined ganglion cell and inner plexiform layer; INL = 
inner nuclear layer.
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Intraretinal multilayer segmentation
The mean macular thickness values for inner retinal layers 
(mRNFL, GCIPL, INL) of the different groups are sum-
marized in Table 2. A graphical representation of the spatial 
changes of CIS patients compared to the matching controls 
is given in Figure 3.
Analysis of the central macular area (6 mm in diameter 
around the fovea) showed significant reduction in mRNFL 
thickness in CIS-ON eyes, but not for CIS-SON and CIS-
NON in comparison to matched controls (Table 2). Spatial 
difference maps showed that mRNFL thinning was most 
prominent in close proximity to the optic nerve head (Figure 
3(a), white arrows). Here, even for CIS-NON eyes mRNFL 
thinning was visible very close to the optic nerve head. It 
should be noted that macular volume scans are not designed 
to investigate the papillary region and that this area is highly 
penetrated by blood vessels, potentially causing segmenta-
tion errors; thus, the mRNFL results have to be evaluated 
with caution.
All patient groups showed reduced GCIPL thickness 
compared to the matched healthy controls. Spatial differ-
ences of the GCIPL were found in the perimacular region 
(Figure 3(b)) and statistical analysis of the GCIPL con-
firmed that the thickness in this area was significantly 
reduced for all patient groups compared to controls (Table 
2). The thinning in CIS-ON and CIS-SON eyes was more 
pronounced than in the CIS-NON group, while the spatial 
distribution of changes was similar. Please refer to the sup-
plementary material for detailed data on the analysis of the 
GCL and IPL individually.
Analogous to pRNFL and TMV, we analysed a potential 
correlation between VEP latencies and intraretinal layer 
thicknesses: mRNFL (R2 = 0.203, p < 0.001) and GCIPL 
(R2 = 0.315, p < 0.001) were significantly correlated to 
VEP latencies (supplementary Figure 2). There was no 
correlation of intraretinal layer thicknesses or VEP laten-
cies with symptom onset in the CIS-NON group (supple-
mentary Figure 3).
Discussion
We analysed intraretinal changes in a cohort of CIS patients, 
which included both eyes with confirmed previous ON, 
eyes with suspected ON, and eyes without evidence of ON 
compared to age- and sex-matched healthy controls. 
Notably, we identified significant thinning of GCIPL in the 
eyes of CIS patients without any clinical history of ON or 
suspected previous subclinical ON as determined by VEP 
changes. A supplementary analysis using distinct GCL and 
IPL thicknesses localized this GCIPL thinning to the GCL 
in CIS-NON patients. Additionally, and as expected, eyes 
with a confirmed history of ON showed an even more pro-
nounced thinning of retinal layers. In contrast, INL appeared 
unaltered. Our data indicate that retinal neuronal damage 
can accompany CIS independently of a prior history of ON.
Three previous studies have investigated retinal changes 
in CIS patients: The first study failed to detect pRNFL or 
TMV reduction in the eyes of CIS patients without prior 
ON.21 A second study reported no retinal damage in the 
eyes of patients with isolated unilateral ON.22 However, 
Table 2. Mean (SD) retinal layer thickness and total macular volume results.
Retinal layer HC (matched to CIS-NON) CIS-NON Regression coefficienta Standard errora P valuea)
pRNFL (µm) 100.69 (8.01) 99.94 (11.28) −1.01 2.13 0.636
TMV (mm3) 8.724 (0.321) 8.570 (0.362) −0.16 0.07 0.031
mRNFL (µm) 39.73 (4.45) 38.76 (4.32) −1.30 0.96 0.173
GCIPL (µm) 71.27 (4.52) 68.88 (5.52) −2.48 1.12 0.027
INL (µm) 33.76 (2.19) 33.39 (2.01) −0.22 0.46 0.626
Retinal layer HC (matched to CIS-SON) CIS-SON Regression coefficienta Standard errora P valuea)
pRNFL (µm) 101.75 (8.25) 87.49 (11.29) −14.68 5.97 0.014
TMV (mm3) 8.866 (0.465) 8.392 (0.358) −0.44 0.26 0.091
mRNFL (µm) 42.01 (4.52) 37.31 (4.56) −4.70 2.62 0.073
GCIPL (µm) 71.45 (4.87) 63.15 (7.43) −7.62 3.85 0.048
INL (µm) 34.49 (2.42) 32.99 (0.96) −1.31 1.05 0.212
Retinal layer HC (matched to CIS-ON) CIS-ON Regression coefficienta Standard errora P valuea
pRNFL (µm) 101.36 (7.44) 82.08 (18.02) −20.15 4.62 <0.001
TMV (mm3) 8.746 (0.335) 8.265 (0.350) −0.48 0.11 <0.001
mRNFL (µm) 39.89 (4.57) 32.14 (5.64) −8.05 1.68 <0.001
GCIPL (µm) 71.57 (4.62) 58.69 (9.77) −3.68 2.64 <0.001
INL (µm) 34.34 (2.38) 34.86 (2.17) 0.64 0.75 0.397
HC: healthy control eyes; CIS-NON: patient eyes without history of optic neuritis and VEP P100 ≤ 115 ms; CIS-SON: eyes with VEP P100 latency > 115 
ms but no ON diagnosis; CIS-ON: patient eyes with clinical ON diagnosis; SD: standard deviation; pRNFL: peripapillary retinal nerve fiber layer; TMV: total 
macular volume; mRNFL: macular retinal nerve fiber layer; GCIPL: combined ganglion cell and inner plexiform layer; INL: inner nuclear layer.
aStatistical parameters of the comparison of CIS patients to the corresponding matching controls using generalized estimation equation models.
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these studies were conducted before the introduction of 
spectral-domain OCT (SD-OCT), the superior spatial reso-
lution of which over time-domain OCT (TD-OCT)23 allows 
for the investigation of intraretinal layers.24 Previously and 
in particular, in the above studies, retinal alterations may 
have simply not been detectable by TD-OCT and, more 
importantly, GCIPL changes that can only quantified using 
SD-OCT might be superior for detecting even subtle neuro-
degeneration in CIS over pRNFL. Peripapillary RNFL also 
failed to detect differences in our groups, suggesting that 
this parameter is in general less sensitive for detecting MS 
pathology than new intraretinal layer measurements like 
GCIPL. With this in mind, the failure to detect significant 
pRNFL alterations in our CIS-NON cohort may simply be 
a power issue. A third recent study comprising 45 CIS 
patients showed a reduction of pRNFL but not TMV using 
SD-OCT.25
The present study is the first to investigate intraretinal 
layer changes or detect retinal neurodegeneration inde-
pendent from ON in a larger cohort of CIS patients. A 
recent study that reported reduction of the GCIPL in MS 
patients with and without a history of ON included seven 
CIS patients while the remaining patients had long-stand-
ing diagnoses of MS, which precluded reliable assessment 
of retinal damage in early disease stages.26 Other studies 
have shown INL impairment (i.e. microcystic macular 
oedema) in MS patients with longer disease duration.11,14 
Such changes were not detected in our CIS patients, sug-
gesting that INL impairment might be a symptom of later or 
more severe disease stages.
Our finding that damage to the GCIPL is detectable in 
CIS eyes without clinical history of ON and with normal 
VEP latency lends additional support to the increasingly 
widespread understanding of MS as both a demyelinating 
and neurodegenerative disease.27 We show that neurodegen-
eration is not, in fact, limited to advanced disease stages, in 
which it is considered responsible for the continuous pro-
gression of neurological disability, even in the absence of 
relapses. Instead, neurodegeneration can begin very early in 
disease development. Our data corroborate MRI data show-
ing neuroaxonal damage during the very earliest MS 
stages,4,28 as well as histopathology data from brain 29 and 
eye,13 and from experimental autoimmune encephalomyeli-
tis.30,31 In line with previous investigations, our study pro-
vides evidence that inflammatory attacks to the optic nerve 
to the extent of a clinical or subclinical ON may not be a 
pre-requisite for damage to the retinal GCIPL.26
Our finding that neuronal retinal damage begins during 
very early disease stages raises urgent questions, the 
answers to which may challenge our understanding of the 
underlying pathology and mechanisms of MS.32 Is the dam-
age we found in the retina a consequence of the retrograde 
degeneration of retinal nerve fibres that occurs as a conse-
quence of autoimmune brain inflammation in MS? If the 
answer is yes, it follows that retrograde RNFL damage 
would subsequently initiate a degenerative process in the 
GCL via a dying back mechanism. Indeed, the hypothesis 
that retrograde retinal neuroaxonal damage takes place both 
after ON as well as brain inflammation without clinical ON 
is supported by experimental animal data from intracranial 
optic nerve sections.33 Here, ocular pathology was shown 
to be limited to the inner retina. Evidence for inner retinal 
layer damage has been further provided by the first large 
scale pathological description of retinae from autopsied MS 
patients showing – apart from the anticipated extensive 
axonal damage – neuronal loss in both the GCL and the 
INL.13 In contrast, a recent OCT study has suggested a pri-
mary retinal pathology as a novel distinct subtype of MS, 
which would implicate that a dying back pathomechanism 
does not apply to all patients:24 the study identified MS 
patients exhibiting substantial reduction of TMV and sig-
nificant thinning of the outer and inner nuclear layers 
despite normal RNFL values. The authors suggested that 
retinal pathology in this disease subtype (termed ‘macular 
thinning predominant’) occurs independently of optic nerve 
pathology and may be a harbinger of a more aggressive dis-
ease course. However, these findings have yet to be con-
firmed by other groups and with other OCT devices in 
larger cohorts.34
Some important caveats of our study should be noted. 
Firstly, undetected subclinical ON episodes in our patient 
cohort may have skewed our results. However, we dealt 
with this potential cohort bias swiftly by conducting a thor-
ough clinical assessment and examination of the individual 
patients. Additionally, each patient had to undergo VEP: 
Eyes with P100 latency suspicious for ON were classified 
as subclinical ON and not as unaffected eyes. Furthermore, 
all patients received MRI as proof that a confirmed diagno-
sis of MS could not yet be established. Although this 
approach cannot be guaranteed to prevent all errors in ON 
identification, it does ensure that the risk of misclassifica-
tion as CIS-NON or MS is negligible and that the conclu-
sions drawn from our data are valid.
A further limitation of our study is that we could not cor-
relate morphological data to functional visual measures 
such as low contrast letter acuity. However, we are cur-
rently addressing this aspect in an ongoing CIS study that 
includes Sloan charts as suggested by a previous study.35 
The high number of statistical analyses in comparison to 
the relatively low number of patients should also be noted. 
As we did not perform a previous power calculation and 
since OCT parameters are related and thus likely corre-
lated, we did not correct for multiple comparisons, since 
doing so would have likely caused an overcorrection. We 
did carefully examine our cohorts for a possible influence 
of outliers and distribution effects, finding no such effect. 
However, it is important to reproduce our findings in an 
independent cohort.
Segmentation of intraretinal layers is a novel technique 
and no studies have been performed so far to better 
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understand how segmentation-derived results relate to in-
vivo morphological changes that appear in MS (e.g. 
through histopathological studies). However, a number of 
recent studies have successfully applied intraretinal seg-
mentation,9,14,17,26,36 and comparison of different segmenta-
tion techniques showed excellent reproducibility and 
reliability.37 We have investigated reliability of the novel 
algorithm applied in this study in a cross-centre inter-rater 
reliability study on a defined set of OCT macular B-scans. 
Results support the excellent reliability of intraretinal seg-
mentation reported by others,37 with the exception that no 
histopathological correlation has been performed so far 
(publication in preparation). However, GCL and IPL are 
still difficult to differentiate in OCT scans and therefore we 
based our study results mostly on the combined layer of 
both (GCIPL) and present individual layer analyses as sup-
plementary data only.
Of note is the large amount of eyes that were classified 
as suspected ON (n = 7) in comparison to the number of 
eyes with definite clinical ON (n = 16). Retinal layer-thin-
ning in these eyes was in-between NON and ON eyes, fur-
ther supporting the notion that optic nerve inflammation is 
not a yes or no event. Instead, substantial damage might be 
caused by optic nerve inflammation before clinical visibil-
ity in form of an apparent clinical ON might be established. 
As our cohort comprised only patients with CIS, failure to 
detect subclinical ON potentially might compromise the 
discrimination between CIS patients and patients who 
already have definite MS. Clearly, detection of subclinical 
alterations in visual and other functional systems urgently 
needs improvement. Our study did not investigate the dis-
criminatory properties of OCT and VEP between CIS and 
MS patients, and consequently, this question must be 
addressed by a future study.
In summary, our study shows that retinal neurodegener-
ation is already detectable in CIS patients and is dependent 
but importantly also independent of clinical relapses (i.e. 
ON). Accordingly, irreversible neuronal damage in MS 
might be much more prevalent than previously thought. 
Long-term follow-up of our study patients, who exhibited 
very early substantial and presumably irreversible neuroax-
onal damage, is vital to ascertain diagnosis in patients likely 
to develop MS as early as possible.
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